Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.66 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224597 | 0.90 | ERCC1 (0.74) | ERCC1ERCC4KMT2AMEN1GAA | |
| SCHEMBL29224595 | 0.90 | ERCC1 (0.74) | ERCC1ERCC4KMT2AMEN1GAA | |
| SCHEMBL29224596 | 0.90 | ERCC1 (0.74) | ERCC1ERCC4KMT2AMEN1GAA | |
| SCHEMBL6094268 | 0.87 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6096835 | 0.87 | ALDH1A1 (0.58) | ERCC1ERCC4KMT2AMEN1ALDH1A1 | |
| SCHEMBL6096837 | 0.87 | ALDH1A1 (0.58) | ERCC1ERCC4KMT2AMEN1ALDH1A1 | |
| SCHEMBL6096841 | 0.87 | ALDH1A1 (0.58) | ERCC1ERCC4KMT2AMEN1ALDH1A1 | |
| SCHEMBL10693790 | 0.83 | KMT2A (0.60) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5018017 | 0.82 | ALDH1A1 (0.66) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL10054191 | 0.82 | POLB (0.67) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | claimed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | claimed |
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1440052-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037847-A1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | ERCC1 4844/4885ERCC4 4794/4885KMT2A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.